Discovery of highly selective and orally active lysophosphatidic acid receptor-1 antagonists with potent activity on human lung fibroblasts

Journal of Medicinal Chemistry

Volumn 55, Issue 17, 2012, Pages 7920-7939

  Qian, Yimin ^a   Hamilton, Matthew ^a   Sidduri, Achyutharao ^a   Gabriel, Stephen ^a   Ren, Yonglin ^a   Peng, Ruoqi ^a   Kondru, Rama ^a   Narayanan, Arjun ^a   Truitt, Terry ^b   Hamid, Rachid ^b   Chen, Yun ^b   Zhang, Lin ^a   Fretland, Adrian J ^c   Sanchez, Ruben Alvarez ^c   Chang, Kung Ching ^a   Lucas, Matthew ^a   Schoenfeld, Ryan C ^a   Laine, Dramane ^a   Fuentes, Maria E ^a   Stevenson, Christopher S ^a   Budd, David C ^a   more..

^a Small Molecule Research   (United States)

^b Discovery Technology   (Finland)

^c Drug Metabolism and Pharmacokinetics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; LUNG FIBROBLAST;

ADMINISTRATION, ORAL; ANIMALS; DRUG DISCOVERY; FIBROBLASTS; HUMANS; LUNG; MAGNETIC RESONANCE SPECTROSCOPY; MICE; PYRAZOLES; RECEPTORS, LYSOPHOSPHATIDIC ACID; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84866330250     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301022v     Document Type: Article

References (33)

1. Datta, A.; Scotton, C. J.; Chambers, R. C. Novel therapeutic approaches for pulmonary fibrosis Br. J. Pharmacol. 2011, 163 (1) 141-172
2. Scotton, C. J.; Chambers, R. C. Molecular targets in pulmonary fibrosis: the myofibroblast in focus Chest 2007, 132 (4) 1311-1321 (Pubitemid 47621009)
3. Parrill, A. L.; Baker, D. L. Autotaxin inhibitors: a perspective on initial medicinal chemistry efforts Expert Opin. Ther. Pat. 2010, 20 (12) 1619-1625
4. Lin, M. E.; Herr, D. R.; Chun, J. Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance Prostaglandins Other Lipid Mediators 2010, 91 (3-4) 130-138
5. Choi, J. W.; Herr, D. R.; Noguchi, K.; Yung, Y. C.; Lee, C. W.; Mutoh, T.; Lin, M. E.; Teo, S. T.; Park, K. E.; Mosley, A. N.; Chun, J. LPA receptors: subtypes and biological actions Annu. Rev. Pharmacol. Toxicol. 2010, 50, 157-186
6. Mutoh, T.; Rivera, R.; Chun, J. Insights into the pharmacological relevance of lysophospholipid receptors Br. J. Pharmacol. 2012, 165 (4) 829-844
7. Shiomi, T.; Boudreault, F.; Padem, N.; Higashiyama, S.; Drazen, J. M.; Tschumperlin, D. J. Lysophosphatidic acid stimulates epidermal growth factor-family ectodomain shedding and paracrine signaling from human lung fibroblasts Wound Repair Regener. 2011, 19 (2) 229-240
8. Yin, Z.; Watsky, M. A. Chloride channel activity in human lung fibroblasts and myofibroblasts Am. J. Physiol. Lung Cell Mol. Physiol. 2005, 288 (6) L1110-1116
9. Mio, T.; Liu, X.; Toews, M. L.; Rennard, S. I. Lysophosphatidic acid augments fibroblast-mediated contraction of released collagen gels J. Lab. Clin. Med. 2002, 139 (1) 20-27 (Pubitemid 34197034)
10. Pradere, J. P.; Klein, J.; Gres, S.; Guigne, C.; Neau, E.; Valet, P.; Calise, D.; Chun, J.; Bascands, J. L.; Saulnier-Blache, J. S.; Schanstra, J. P. LPA1 receptor activation promotes renal interstitial fibrosis J. Am. Soc. Nephrol. 2007, 18 (12) 3110-3118 (Pubitemid 350223970)
11. Tager, A. M.; LaCamera, P.; Shea, B. S.; Campanella, G. S.; Selman, M.; Zhao, Z.; Polosukhin, V.; Wain, J.; Karimi-Shah, B. A.; Kim, N. D.; Hart, W. K.; Pardo, A.; Blackwell, T. S.; Xu, Y.; Chun, J.; Luster, A. D. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak Nat. Med. 2008, 14 (1) 45-54
12. Xue, J.; Gan, L.; Li, X.; Li, J.; Qi, G.; Wu, Y.; Fu, X.; Mao, Q.; Ao, R.; Lang, J.; Lu, Y. Effects of lysophosphatidic acid and its receptors LPA(1/3) on radiation pneumonitis Oncol. Rep. 2010, 24 (6) 1515-1520
13. Rancoule, C.; Pradere, J. P.; Gonzalez, J.; Klein, J.; Valet, P.; Bascands, J. L.; Schanstra, J. P.; Saulnier-Blache, J. S. Lysophosphatidic acid-1-receptor targeting agents for fibrosis Expert Opin. Invest. Drugs 2011, 20 (5) 657-667
14. Fells, J. I.; Tsukahara, R.; Liu, J.; Tigyi, G.; Parrill, A. L. Structure-based drug design identifies novel LPA3 antagonists Bioorg. Med. Chem. 2009, 17 (21) 7457-7464
15. Heasley, B. H.; Jarosz, R.; Lynch, K. R.; Macdonald, T. L. Initial structure-activity relationships of lysophosphatidic acid receptor antagonists: discovery of a high-affinity LPA1/LPA3 receptor antagonist Bioorg. Med. Chem. Lett. 2004, 14 (11) 2735-2740 (Pubitemid 38569729)
16. East, J. E.; Carter, K. M.; Kennedy, P. C.; Schulte, N. A.; Toews, M. L.; Lynch, K. R.; Macdonald, T. L. Development of a phosphatase-resistant, L-tyrosine derived LPA1/LPA3 dual antagonist MedChemComm 2011, 2 (4) 325-330
17. Ohta, H.; Sato, K.; Murata, N.; Damirin, A.; Malchinkhuu, E.; Kon, J.; Kimura, T.; Tobo, M.; Yamazaki, Y.; Watanabe, T.; Yagi, M.; Sato, M.; Suzuki, R.; Murooka, H.; Sakai, T.; Nishitoba, T.; Im, D. S.; Nochi, H.; Tamoto, K.; Tomura, H.; Okajima, F. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors Mol. Pharmacol. 2003, 64 (4) 994-1005 (Pubitemid 37153068)
18. Swaney, J. S.; Chapman, C.; Correa, L. D.; Stebbins, K. J.; Bundey, R. A.; Prodanovich, P. C.; Fagan, P.; Baccei, C. S.; Santini, A. M.; Hutchinson, J. H.; Seiders, T. J.; Parr, T. A.; Prasit, P.; Evans, J. F.; Lorrain, D. S. A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model Br. J. Pharmacol. 2010, 160 (7) 1699-1713
19. Swaney, J. S.; Chapman, C.; Correa, L. D.; Stebbins, K. J.; Broadhead, A. R.; Bain, G.; Santini, A. M.; Darlington, J.; King, C. D.; Baccei, C. S.; Lee, C.; Parr, T. A.; Roppe, J. R.; Seiders, T. J.; Ziff, J.; Prasit, P.; Hutchinson, J. H.; Evans, J. F.; Lorrain, D. S. Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist J. Pharmacol. Exp. Ther. 2011, 336 (3) 693-700
20. Castelino, F. V.; Seiders, J.; Bain, G.; Brooks, S. F.; King, C. D.; Swaney, J. S.; Lorrain, D. S.; Chun, J.; Luster, A. D.; Tager, A. M. Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma Arthritis Rheum. 2011, 63 (5) 1405-1415
21. Xu, M. Y.; Porte, J.; Knox, A. J.; Weinreb, P. H.; Maher, T. M.; Violette, S. M.; McAnulty, R. J.; Sheppard, D.; Jenkins, G. Lysophosphatidic acid induces alphavbeta6 integrin-mediated TGF-beta activation via the LPA2 receptor and the small G protein G alpha(q) Am. J. Pathol. 2009, 174 (4) 1264-1279
22. Beck, H. P.; Kohn, T.; Rubenstein, S.; Hedberg, C.; Schwandner, R.; Hasslinger, K.; Dai, K.; Li, C.; Liang, L.; Wesche, H.; Frank, B.; An, S.; Wickramasinghe, D.; Jaen, J.; Medina, J.; Hungate, R.; Shen, W. Discovery of potent LPA2 (EDG4) antagonists as potential anticancer agents Bioorg. Med. Chem. Lett. 2008, 18 (3) 1037-1041 (Pubitemid 351179347)
23. Lukyanov, S. M.; Bliznets, I. V.; Shorshnev, S. V.; Aleksandrov, G. G.; Stepanov, A. E.; Vasil'ev, A. A. Microve-assisted synthesis and transformations of sterically hindered 3-(5-tetrazolyl)pyridines Tetrahedron 2006, 62, 1849-1863 (Pubitemid 43152086)
24. Meanwell, N. A. Synopsis of some recent tactical application of bioisosteres in drug design J. Med. Chem. 2011, 54 (8) 2529-2591
25. Sardar, V. M.; Bautista, D. L.; Fischer, D. J.; Yokoyama, K.; Nusser, N.; Virag, T.; Wang, D. A.; Baker, D. L.; Tigyi, G.; Parrill, A. L. Molecular basis for lysophosphatidic acid receptor antagonist selectivity Biochim. Biophys. Acta 2002, 1582 (1-3) 309-317 (Pubitemid 34634143)
26. Pierce, A. C.; ter Haar, E.; Binch, H. M.; Kay, D. P.; Patel, S. R.; Li, P. CH-O and CH-N hydrogen bonds in ligand design: a novel quinazolin-4- ylthiazol-2-ylamine protein kinase inhibitors J. Med. Chem. 2005, 48, 1278-1281 (Pubitemid 40270474)
27. Hayashi, M.; Okabe, K.; Kato, K.; Okumura, M.; Fukui, R.; Fukushima, N.; Tsujiuchi, T. Differential function of lysophosphatidic acid receptors in cell proliferation and migration of neuroblastoma cells Cancer Lett. 2012, 316 (1) 91-96
28. Ramirez, G.; Hagood, J. S.; Sanders, Y.; Ramirez, R.; Becerril, C.; Segura, L.; Barrera, L.; Selman, M.; Pardo, A. Absence of Thy-1 results in TGF-beta induced MMP-9 expression and confers a profibrotic phenotype to human lung fibroblasts Lab. Invest. 2011, 91 (8) 1206-1218
29. Funke, M.; Zhao, Z.; Xu, Y.; Chun, J.; Tager, A. M. The lysophosphatidic acid receptor LPA1 promotes epithelial cell apoptosis after lung injury Am. J. Respir. Cell Mol. Biol. 2012, 46 (3) 355-364
30. Yamamoto, T.; Fujita, K.; Asari, S.; Chiba, A.; Kataba, Y.; Ohsumi, K.; Ohmuta, N.; Iida, Y.; Ijichi, C.; Iwayama, S.; Fukuchi, N.; Shoji, M. Synthesis and evaluation of isoxazole derivatives as lysophosphatidic acid (LPA) antagonists Bioorg. Med. Chem. Lett. 2007, 17 (13) 3736-3740 (Pubitemid 46901102)
31. Hutchinson, J. H.; Seiders, T. J.; Wang, B. Compounds as Lysophosphatidic Acid Receptor Antagonists. Patent application WO2011/017350.
32. Hutchinson, J. H.; DeArmond, I. M.; Seiders, T. J. Lysophosphatidic Acid Receptor Antagonist for the Treatment of Dermal Conditions. Patent application WO2011/159635.
33. Brittain, J. E.; Seiders, T. J.; Hutchinson, J. H.; King, C. D.; Rosso, V. W. Patent application WO2012/078805.